KPTI

Karyopharm Therapeutics Inc.
CAPPED RATING

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class drugs directed against nuclear transport and related targets to treat cancer and other diseases.

Karyopharm Therapeutics Inc. (KPTI) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
B-
Factor Score 3.0 / 5.0
Growth
C+
Factor Score 2.8 / 5.0
Profitability
B
Factor Score 3.4 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.0
EV / EBITDA -3.2
Rev Growth YoY -11.9%
Gross Margin 99.1%
Price Return 3M N/A
Price Return 12M N/A
Catalyst Signal 0.00
Market Cap $394.7K
TTM Revenue $146.6M
Price / Sales 0.0
ROE N/A

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 B- (3.0) C+ (2.8) B (3.4) C+ (2.5) F (0.0) C (2.3)
2026-11-06 B- (3.0) C+ (2.7) B (3.4) F (0.3) F (0.0) C- (1.9)
2026-10-30 B- (3.0) C+ (2.6) B+ (3.5) F (0.7) C+ (2.7) C (2.5)
2026-10-23 B- (3.0) C+ (2.6) B (3.5) F (0.4) F (0.0) C- (1.9)
2026-10-16 B- (3.0) C+ (2.6) B (3.5) F (0.4) F (0.0) C- (1.9)
Page 1 of 5